1705 / 1851
Conclusions
1. SCPRT = CRT in resectable cancer
2. cN+ probably inaccurate - most patients
pN0
3. Radio-sensitizing 5FU-based CRT with sub
therapeutic oxaliplatin ?
4. But minimal benefit for T3N0 on mets
5. Immunotherapy is coming